1. Home
  2. NABL vs DVAX Comparison

NABL vs DVAX Comparison

Compare NABL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NABL
  • DVAX
  • Stock Information
  • Founded
  • NABL 2000
  • DVAX 1996
  • Country
  • NABL United States
  • DVAX United States
  • Employees
  • NABL N/A
  • DVAX N/A
  • Industry
  • NABL Computer Software: Prepackaged Software
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NABL Technology
  • DVAX Health Care
  • Exchange
  • NABL Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • NABL 1.5B
  • DVAX 1.2B
  • IPO Year
  • NABL N/A
  • DVAX 2004
  • Fundamental
  • Price
  • NABL $7.99
  • DVAX $11.25
  • Analyst Decision
  • NABL Buy
  • DVAX Buy
  • Analyst Count
  • NABL 4
  • DVAX 4
  • Target Price
  • NABL $9.31
  • DVAX $26.50
  • AVG Volume (30 Days)
  • NABL 667.1K
  • DVAX 1.6M
  • Earning Date
  • NABL 11-06-2025
  • DVAX 11-05-2025
  • Dividend Yield
  • NABL N/A
  • DVAX N/A
  • EPS Growth
  • NABL N/A
  • DVAX N/A
  • EPS
  • NABL N/A
  • DVAX N/A
  • Revenue
  • NABL $497,665,000.00
  • DVAX $330,514,000.00
  • Revenue This Year
  • NABL $9.79
  • DVAX $23.23
  • Revenue Next Year
  • NABL $8.97
  • DVAX $16.57
  • P/E Ratio
  • NABL N/A
  • DVAX N/A
  • Revenue Growth
  • NABL 8.65
  • DVAX 26.73
  • 52 Week Low
  • NABL $6.07
  • DVAX $9.20
  • 52 Week High
  • NABL $11.40
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • NABL 50.60
  • DVAX 66.48
  • Support Level
  • NABL $7.56
  • DVAX $9.92
  • Resistance Level
  • NABL $8.74
  • DVAX $11.24
  • Average True Range (ATR)
  • NABL 0.31
  • DVAX 0.34
  • MACD
  • NABL 0.01
  • DVAX 0.11
  • Stochastic Oscillator
  • NABL 34.32
  • DVAX 87.09

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: